CRISPR-Cas9 for TTR Amyloidosis; Osmotic Demyelination Syndrome


Listens: 0

Neurology® Podcast


In the first part of the podcast, Dr. Alberto Espay talks with Prof. Julian Gillmore about CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. In the second segment, Dr. Pearce Korb discusses the long-term outcomes of osmotic demyelination syndrome in an updated cohort with Dr. Whitney Fitts.